

EVER Valinject GmbH
Oberburgau 3
4866 Unterach am Attersee
Austria

12.03.2018

ANSM
DMFR – PGF-AMM-930 (this is the code for MA hybrid / generic applications)
143-147, Bd Anatole France
F-93285 Saint-Denis cedex
France

**Subject: Submission of Application Dossier(s) for Marketing Authorisation of
Dexmedetomidine EVER Pharma 100 micrograms/ml concentrate for solution for infusion
DK/H/2619/001/E/001**

CESP number: 661848

Dear Sirs,

We are pleased to submit our Application Dossier(s) for a Mutual Recognition Procedure which details are as follows:

Name of the medicinal product(s) (in the RMS): Dexmedetomidine EVER Pharma
Pharmaceutical form(s) and strength(s): Concentrate for solution for infusion (100 micrograms/ml)
INN/active substance(s): Dexmedetomidine Hydrochloride
ATC Code(s): N05CM18

Legal Basis of the Application(s):

When appropriate, please indicate:

- | | | |
|---|---|--|
| - Use of European Reference Medicinal Product | <input checked="" type="checkbox"/> Yes | <input type="checkbox"/> No |
| - If the strength(s) of the Reference MP differs between RMS/CMS | <input type="checkbox"/> Yes | <input checked="" type="checkbox"/> No |
| - If the pharmaceutical form(s) of the Reference MP differs between RMS/CMS | <input type="checkbox"/> Yes | <input checked="" type="checkbox"/> No |
| - If the indication(s) of the Reference MP differs between RMS/CMS | <input type="checkbox"/> Yes | <input checked="" type="checkbox"/> No |

You will find enclosed the submission dossier as specified hereafter:

eCTD format, Sequence number: 0015

We confirm that all future submissions for this specific product will be submitted in this same format.

The eCTD has passed the applicant's internal technical validation (all P/F criteria passed and all BP criteria have been fulfilled up to our best knowledge) using eCTDmanager, Extedo, Version 4 – SP8 (4.0.8.058).

We confirm that the electronic submission has been checked with an up-to-date and state-of-the-art virus checker.

- The relevant fees have been paid.
- The Risk Management Plan in module 1.8.2 is similar to the one approved in the procedure DK/H/2619/001/DC.

The local PV person, located in France, is:

Tel:

Fax:

e-mail:

The local exploitant is:

We, EVER Valinject GmbH, hereby certify that the dossier submitted to the RMS and CMS(s) are fully identical.

There are, however, some different **national** documents (<cover letter><application form><specific national requirements>) that are submitted to the relevant RMS/CMS only, **outside** the eCTD dossier

There are, however, some different **national** documents (<cover letter><application form><specific national requirements>) that are submitted to the relevant RMS/CMS only, **within** the eCTD dossier

Yours sincerely,

Regulatory Affairs

Phone:

Email address: @everpharma.com

Email address for technical validation issues: @everpharma.com